This demo of interactive floor tiles developed by researchers at the University of McGill in Quebec, Canada, responds to a user with visual, audio and physical cues. The floor tiles could be used in an augmented reality setting, for training, rehabilitation, or entertainment.
In October 2009, MIT’s Solar Electric Vehicle Team competed in the World Solar Challenge in Australia, the world’s longest solar-powered car race. Technology Review sat down with team captain, Alex Arambula, and team member, Chris Pentacoff, to discuss preparing for and racing in Australia.
At Rice University in Houston, TX, researchers are making carbon nanotubes into long fibers that are lightweight, conductive, and strong.
What the 10 technologies tell you about us.
Media Lab Complex encourages collaboration
As one of this year’s TR10 innovators Marie-Jose Montpetit is helping companies like BT develop better ways to integrate social media with television. We asked her about how her system works and what benefits is might bring to viewers.
One of this year’s TR10 innovators, Joule Biotechnologies, is developing a way to make biofuels without agricultural plants, using genetically engineered photosynthetic bacteria. We asked founder Noubar Afeyan about how his biofuel differed from others, and how long it might be before people could be filling their cars with it.
One of this year’s TR10 innovators is Novacem, a British startup trying to solve the emission problem with a new way of making cement. We asked the company’s chief scientist, Nikoloas Vlasopoulos, why traditional cement manufacture is responsible for so much carbon dioxide and how the new cement gets around the problem.
TR10 innovator, Joseph Hellerstein, is trying to make life easier for programmers by creating tools that can take over data management within a cloud. We asked him about the potential of cloud computing and how his approach will unlock that potential.
At Genentech, one of this year’s TR10 innovators, Germaine Fuh is developing a new variety of drug that can target more than one type of molecule, potentially reducing costs and simplifying treatment. We asked Fuh how it worked and what it might mean for patients.